Armistice Capital’s Accelerate Diagnostics AXDX Stock Holding History

Armistice Capital’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,879,227	Closed	-$1.32M	–	208
2025 Q1	$1.32M	Sell	1,879,227 -198,773	-10%	-$227K	0.02%	157
2024 Q4	$2.49M	Sell	2,078,000 -23,000	-1%	-$38.2K	0.03%	144
2024 Q3	$3.59M	Buy	2,101,000 +493,000	+31%	+$730K	0.06%	139
2024 Q2	$1.88M	Sell	1,608,000 -238,000	-13%	-$249K	0.02%	146
2024 Q1	$1.83M	Buy	+1,846,000	New	+$2.92M	0.02%	146

Other funds holding AXDX

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

Armistice Capital's AXDX Position: Q2 2025 in Review

Armistice Capital sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 1,879,227 shares — an estimated $1.32M sold.

Armistice Capital first reported a position in AXDX in Q1 2024 and held it in 5 quarters. The position peaked at $3.59M in Q3 2024. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

Armistice Capital reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
Armistice Capital sold 1,879,227 Accelerate Diagnostics shares in Q2 2025, an estimated $1.32M.
Armistice Capital first reported a position in Accelerate Diagnostics in Q1 2024 and held it in 5 quarters.
Armistice Capital's Accelerate Diagnostics position peaked at $3.59M in Q3 2024.
3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.